Skip to main content Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: STTK

Shattuck Labs, Inc.

Healthcare | Biotechnology
$7.05 as of 2026-09-05 03:41 UTC
Market Cap$450M
Volume70.3K
EPS (TTM)$-0.70

Shattuck Labs, Inc. (NASDAQ: STTK) is a $450M biotechnology company trading at $7.05. Figures from SEC EDGAR and market feeds; updated 2026-09-05 03:41 UTC.

What Shattuck Labs, Inc. does

The company is a clinical-stage biotechnology firm developing monoclonal and bispecific antibodies that block Death Receptor 3 (DR3) to treat inflammatory and immune-mediated diseases. Its lead program, SL-325, is a DR3 blocking antibody designed to inhibit the DR3/TL1A pathway more effectively than existing TL1A blocking antibodies. The company is currently running a Phase 1 trial of SL-325 in healthy volunteers and plans to begin a Phase 2 trial in Crohn's Disease patients.

Summarized from Shattuck Labs, Inc.’s SEC filings · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Quote
Price$7.05
Market cap$450M
Volume70.3K shares
Valuation
EPS (TTM)$-0.70
Price/book5.46×

Revenue, margins & earnings

FY2021: net loss $45M on revenue $30M$30MFY2021FY2022: net loss $102M on revenue $652,000$652,000FY2022FY2023: net loss $87M on revenue $2M$2MFY2023FY2024: net loss $75M on revenue $6M$6MFY2024FY2025: net loss $49M on revenue $1M$1MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-07-07
  • 2026-07-07Shukla Abhinav A.Chief Technical OfficerM410$1.5K
  • 2026-07-07Shukla Abhinav A.Chief Technical OfficerM-410—
  • 2026-07-07Shukla Abhinav A.Chief Technical OfficerSELL-410$2.9K
Sign in to see all transactions →

Company news

View all →

Questions this page answers

What does Shattuck Labs, Inc. do?

The company is a clinical-stage biotechnology firm developing monoclonal and bispecific antibodies that block Death Receptor 3 (DR3) to treat inflammatory and immune-mediated diseases.

What is STTK's valuation?

STTK trades at $7.05, as of 2026-09-05.

When did STTK last file with the SEC?

Shattuck Labs, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-11. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings and public market data feeds, fetched 2026-09-05 03:41 UTC. This page is also available as JSON at /api/data?ticker=STTK and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for STTK and 5,000+ tickers.

Create a free account — keep STTK
For your agent
GET /api/data?ticker=STTK

This page as JSON via rel="alternate" · REST API docs · MCP server (59 tools) · llms.txt